TL/DR –
The U.S. significantly relies on China and India for everyday medications and prescription drugs, with over 80% of active pharmaceutical ingredients in generic drugs being produced overseas. This reliance has exposed a dangerous vulnerability, as U.S. hospitals currently face chronic shortages for more than 250 critical medicines. Solutions such as public-private partnerships, a federal buyer’s market for essential medications, and prioritizing American manufacturing plants could help reduce the U.S.’s dependence on imported pharmaceuticals and boost domestic production.
Lessening US Reliance on Foreign Medication
The US must curtail dependence on China and India for essential medications to protect Americans’ health security. Currently, 90% of Americans’ daily medications are imported, with 80% of the active ingredients in generic drugs originating from overseas, primarily China and India. This heavy reliance has led to chronic shortages in more than 250 critical medicines such as life-saving chemotherapy drugs in US hospitals.
Despite the rapid globalization of the pharmaceutical industry, US policymakers and corporate leaders have largely ignored the need to rebuild domestic drug manufacturing. However, this complacency has exposed a dangerous vulnerability in America’s healthcare system, which is increasingly reliant on overseas medication supply.
Addressing Pharmaceutical Dependence
Last month, the US Senate held bipartisan hearings on the risks of import dependence on medicines. Notable figures such as Sens. Rick Scott and Kirsten Gillibrand have spotlighted the issue, advocating for the ramping up of domestic drug manufacturing. The Trump administration has also taken steps to reverse decades of offshoring, working to restore domestic production across critical sectors like pharmaceuticals.
Public-private partnerships have the potential to significantly influence US healthcare. For example, the recently announced US-South Korea Trade Agreement demonstrates how foreign partnerships can enhance American security. Similar investment strategies should be extended to pharmaceutical and biotechnology manufacturing.
Policies for a Resilient Supply Chain
Earlier this year, the Trump administration issued executive orders to prioritize American manufacturing and restore domestic production capacity. These actions have already facilitated over $350 billion in investments to bolster US production.
Furthermore, JPMorgan Chase announced a $1.5 trillion security and resiliency initiative, which includes $10 billion for domestic supply-chain resilience. This initiative is an excellent blueprint, demonstrating how both the federal government and the private investment community can provide the capital needed to mitigate threats to America’s health security.
A recent Senate hearing suggested several proposals, including the establishment of a federal buyer’s market for essential medications. Such procurement and reimbursement reforms could create investor certainty and stimulate domestic pharmaceutical production. The ultimate goal is to foster scalable, innovative, and advanced manufacturing in the US, thus reducing America’s dangerous dependence on imported pharmaceuticals.
—
Read More Health & Wellness News ; US News